Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
about
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingFatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcomeSerum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese populationPredictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapyEvaluation of 8q24 and 17q risk loci and prostate cancer mortality.Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequencesMolecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancerGenetic variation: effect on prostate cancer.Polymorphisms in genes hydroxysteroid-dehydrogenase-17b type 2 and type 4 and endometrial cancer riskCastration-resistant prostate cancer: new science and therapeutic prospects.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerGenome-wide association study of prostate cancer mortalityGenetic variants of the autophagy pathway as prognostic indicators for prostate cancer.Germline predictors of androgen deprivation therapy response in advanced prostate cancerEthnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.Blood and tissue biomarkers in prostate cancer: state of the art.The genetics of castration-resistant prostate cancer: what can the germline tell us?Androgen receptor: role and novel therapeutic prospects in prostate cancer.Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group.Biomarkers for prostate cancer: present challenges and future opportunities.Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate CancerInherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy.Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.The evolving role of familial history for prostate cancer.Prostate cancer: germline prediction for a commonly variable malignancy.Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.Profiling serum HER-2/NEU in prostate cancer.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Evaluation of the potential antidepressant effects of soybean isoflavones.Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.Castration-resistant prostate cancer: targeted therapies and individualized treatmentDoes genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?Molecular basis for prostate cancer racial disparities.Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.Nicotinamide N-methyltransferase is overexpressed in prostate cancer and correlates with prolonged progression-free and overall survival times.Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancerAssociations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
P2860
Q27025062-16F03E46-ED87-48C3-BF00-C43DD98D0FB0Q27318509-F9902C2C-68EA-4677-BFD6-0567EE09C9DAQ28478038-30B3E5D7-1A3E-409E-9CE6-0DDD1519914CQ28541955-26651844-CC26-46DF-8991-A5A784BC6E29Q30494721-7DB1CD5B-DF09-480B-9E5C-896F72BA3629Q34283623-6BDE43E0-5550-48CC-8755-13A729E98400Q34566518-590E984D-D805-4761-93C8-7DC6B133588BQ34663656-B6424A3F-5105-4F21-8253-843482170AD0Q34708672-7F7729AF-4793-4815-940C-424E64B8CE08Q35076264-BCEE7C2B-1B28-4A13-A620-EDD4B066A510Q35112055-454E8C5A-21EA-4A2E-AAB9-7E441AFD6842Q35399770-18AD1E9A-EEE8-4649-A1BA-5D6CA1284FFFQ36056250-68C9609D-54FA-4C25-86BA-52720618AB76Q36512896-8E094937-DA52-4B66-A2A9-3DB07307E554Q36758880-DB532865-AAE8-4D7B-B40C-7E69C7A0B917Q37127302-8BEF905C-44CE-4E58-9BD6-EFD315C2D1A7Q37201929-ADAEDA5F-CE48-46F6-87D6-D90EE29E26EFQ37233298-0E3D1EF7-F0DD-467B-BD1E-6CD5DA45AC78Q37256846-251C7A18-32F0-4524-ADA8-E638F01163A1Q37264625-711D0ED5-392D-4789-988E-1BCAECC5209CQ37474443-1942D9A7-66DD-486B-AE71-453B5EDC102EQ37496642-482E9416-EEFF-4132-AC02-9BF1B816A35AQ37534512-B8F69449-5738-4C4D-9676-3CE0E30E1E6DQ37613206-7A35D728-1E73-4B00-A146-34F8241490D5Q37793100-F7B98A01-F5A2-40BE-B127-E39F2F10D953Q38043095-21D130E4-D2A1-42B5-94CE-9615B279FA8CQ38165722-8D50F401-C8B6-47AF-A0DD-8D6F90B8E506Q38174595-1D3B2427-8095-4536-AD45-AC378335FC90Q38620751-DDA0ACB4-A5C7-430B-BDB6-2E77B1D51FA0Q38828677-099F9DB0-1F19-48B7-A107-E14B901832C4Q39032104-1B7DCED1-9778-4556-99B3-5843B5AE59ADQ39440957-A951CB68-7328-4732-A680-254AB4F99539Q39511732-129FB5C1-24C7-4FAB-9212-DBDD5B3D79BEQ40152616-3998E473-E33D-4D6C-9C5F-A642017BBFE6Q41334556-CD876279-9BEA-44A0-B08A-E28C9583AFA5Q41508304-A636B694-14EE-4254-BDBD-D01F086D8AA5Q42131119-9C3F2FBA-CFAA-4CCB-8F93-AED7116D3AB4Q42322498-D69D13FC-7FF2-4568-A908-7169BAD0B69FQ42509592-32C64CAA-8768-409E-9DC8-C2AC9EC9F0C9Q42700287-59845816-F7C1-4281-84EF-DB48868BA4D7
P2860
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Inherited variation in the and ...... y in men with prostate cancer.
@ast
Inherited variation in the and ...... y in men with prostate cancer.
@en
Inherited variation in the and ...... y in men with prostate cancer.
@nl
type
label
Inherited variation in the and ...... y in men with prostate cancer.
@ast
Inherited variation in the and ...... y in men with prostate cancer.
@en
Inherited variation in the and ...... y in men with prostate cancer.
@nl
prefLabel
Inherited variation in the and ...... y in men with prostate cancer.
@ast
Inherited variation in the and ...... y in men with prostate cancer.
@en
Inherited variation in the and ...... y in men with prostate cancer.
@nl
P2093
P50
P356
P1476
Inherited variation in the and ...... y in men with prostate cancer.
@en
P2093
Mark Pomerantz
Matthew Freedman
Meredith M Regan
Oliver Sartor
Robert W Ross
Wanling Xie
William K Oh
P304
P356
10.1200/JCO.2007.13.6804
P407
P577
2008-02-01T00:00:00Z